News Releases

Date Title
01/03/2019 Summary ToggleEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and Business Outlook for 2019 during the 37th Annual J.P. Morgan Healthcare Conference
12/20/2018 Summary ToggleEnanta Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
11/26/2018 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
11/13/2018 Summary ToggleEnanta Announces that AbbVie’s MAVYRET™ (glecaprevir/pibrentasvir) Shows High Virologic Cure* Rates in Treatment-Naïve Hepatitis C Patients with Compensated Cirrhosis
10/29/2018 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on November 26 at 4:30 pm ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2018
10/23/2018 Summary ToggleEnanta Pharmaceuticals Announces Positive Phase 1 Results and Initiation of Phase 2a Clinical Study of EDP-938 for Respiratory Syncytial Virus
09/05/2018 Summary ToggleEnanta Pharmaceuticals to Present New Data on its RSV Inhibitor EDP-938 at the 11th International Respiratory Syncytial Virus Symposium
08/27/2018 Summary ToggleEnanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
08/07/2018 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2018
07/16/2018 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on August 7 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Third Quarter Ended June 30, 2018